A5010071356- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- Vascular Anomalies and Treatments
- Transplantation: Methods and Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Heart Failure Treatment and Management
- Medical Imaging and Pathology Studies
- Congenital Heart Disease Studies
- Liver Disease and Transplantation
- Cardiac Arrhythmias and Treatments
- Nitric Oxide and Endothelin Effects
- Renin-Angiotensin System Studies
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Respiratory viral infections research
- Renal Transplantation Outcomes and Treatments
- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Tracheal and airway disorders
- Cardiovascular Disease and Adiposity
- Organ Transplantation Techniques and Outcomes
- Polyomavirus and related diseases
- Heart Rate Variability and Autonomic Control
- Blood Pressure and Hypertension Studies
- Hormonal Regulation and Hypertension
Vanderbilt University Medical Center
2016-2025
Vanderbilt University
2012-2024
University of Arizona
2023
Pulmonary and Allergy Associates
1998-2019
University of California, San Diego
2009-2014
University of Illinois Chicago
2014
University of Chicago
2014
Queen's University
2014
Atrium Health Wake Forest Baptist
2013
National Heart Lung and Blood Institute
2012
Background: Pulmonary hypertension is a progressive and often fatal complication of the scleroderma spectrum disease for which no treatment has been proven effective in randomized trial. Objective: To determine effect epoprostenol on pulmonary secondary to disease. Design: Randomized, open-label, controlled Setting: 17 referral centers. Patients: 111 patients with moderate severe hypertension. Intervention: Epoprostenol plus conventional therapy or alone. Measurements: The primary outcome...
Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the vasoconstrictor effects of endothelin-A while maintaining vasodilator/clearance functions endothelin-B receptors. Patients that was idiopathic, related to connective tissue disease or congenital heart disease, were randomized receive placebo (n = 60), sitaxsentan 100 mg 55), 300 63) orally once daily for 12 weeks. The primary endpoint change in peak VO(2) at Week 12. Secondary endpoints included 6-minute...
The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist epoprostenol, a continuously infused prostaglandin, in the treatment pulmonary arterial hypertension (PAH) was investigated. In this double-blind, placebo-controlled prospective study, 33 patients with PAH started epoprostenol (2 ng·kg −1 min starting dose, up to 14±2 at week 16) were randomised for 16 weeks 2:1 ratio bosentan (62.5 mg b.i.d 4 then 125 ) or placebo. Haemodynamics, exercise...
Background —This report describes the complication of pulmonary vein stenosis with resultant severe hypertension that developed in 2 patients after successful catheter ablation chronic atrial fibrillation. Methods and Results —Three months fibrillation, both progressive dyspnea hypertension. Both were found to have all 4 veins near junction left atrium. Balloon dilation stenotic was performed these patients, improvement Conclusions —The is potentially life-threatening, application...
Pulmonary arterial hypertension (PAH) is a deadly disease with no cure. Alternate conversion of angiotensin II (AngII) to angiotensin-(1–7) (Ang-(1–7)) by angiotensin-converting enzyme 2 (ACE2) resulting in Mas receptor (Mas1) activation improves rodent models PAH. Effects recombinant human (rh) ACE2 PAH are unknown. Our objective was determine the effects rhACE2 We defined molecular Mas1 using porcine pulmonary arteries, measured AngII/Ang-(1–7) levels and conducted phase IIa, open-label...
Epoprostenol has markedly improved the treatment of pulmonary arterial hypertension, although predictors outcome with epoprostenol are not well characterized. From June 1995 through August 2001, 91 patients hypertension were treated at our institution. We analyzed effects long-term to determine features associated outcome. Predictors worse included older age disease onset (hazard ratio 3.2, 95% confidence interval 1.32–7.76 for above median 44 years), World Health Organization functional...
Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires intravenous infusion and associated with adverse effects. The objective this study was to evaluate the effects an analog, treprostinil, hypertension. Ten tertiary care academic institutions hypertension programs participated in these pilot trials. In first trial, treprostinil were compared. second subcutaneous third compared placebo during 8-week period. resulted a similar...
Previous studies have shown that approximately 55% of patients with familial pulmonary arterial hypertension (FPAH) BMPR2 coding sequence mutations. However, direct sequencing does not detect other types heterozygous mutations, such as exonic deletions/duplications.To estimate the frequency deletions/duplications in FPAH.BMPR2 mRNA from lymphoblastoid cell lines 30 families PAH and 14 idiopathic (IPAH) was subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) sequencing....
Analysis of the age onset in heritable pulmonary arterial hypertension (HPAH) has led to hypothesis that genetic anticipation causes younger and death subsequent generations. With accrual pedigree data over multiple decades, we retested this using analyses eliminate truncation exists with shorter duration follow-up.To analyze pedigrees families mutations bone morphogenetic protein receptor type 2 (BMPR2), afflicted two or more generations HPAH, eliminating time bias by including for whom...
Background— Excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) plays an important role in the development idiopathic arterial hypertension (IPAH), whereas a rise cytosolic Ca 2+ concentration triggers PASMC contraction and stimulates proliferation. Recently, we demonstrated that upregulation TRPC6 channel contributes to PASMCs isolated from IPAH patients. This study sought identify single-nucleotide polymorphisms (SNPs) gene promoter are associated with have functional...
Background— Determining the cause for pulmonary hypertension is difficult in many patients. Pulmonary arterial (PAH) differentiated from venous (PVH) by a wedge pressure (PWP) >15 mm Hg PVH. Patients undergoing right heart catheterization evaluation of may be dehydrated and have reduced intravascular volume, potentially leading to falsely low measurement PWP an erroneous diagnosis PAH. We hypothesized that fluid challenge during would identify occult (OPVH). Methods Results— reviewed...